The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASH 2015 | Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events

Name: Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events
Uploaded: 2015-12-04T00:00:00.000Z
Duration: 2 min 21 s
Description: Jacqueline Barrientos, MD, from the North Shore-Long Island Jewish Health System in New York, discusses a recent follow-up study looking at CLL patient outcomes following treatment with ibrutinib, including populations that had no post-trial access to ibrutinib, or those who moved to a comparator. The insights from this study help to inform decisions regarding sequential and salvage treatments.

Jacqueline Barrientos • 4 Dec 2015

ASH 2015

Chronic Lymphocytic Leukemia

Jacqueline Barrientos, MD, from the North Shore-Long Island Jewish Health System in New York, discusses a recent follow-up study looking at CLL patient outcomes following treatment with ibrutinib, including populations that had no post-trial access to ibrutinib, or those who moved to a comparator. The insights from this study help to inform decisions regarding sequential and salvage treatments.